

Primary Pathway Decision Logic


The goal of Pathways is to reduce unwarranted variability in care to improve outcomes for patients.

Via Pathway Philosophy & Process

- Even when comparative evidence is not clear, driving to **standardization** based on the consensus of practicing oncologists is better than providing no guidance.
- Pathways are intended to address **common but not all patient presentations**; hence, a goal of 80% On Pathway.
- Other Patient Scenarios can be created as secondary On Pathway options, but only for specific patient scenarios.
- If the Committee believes that one treatment is more efficacious than another, then that treatment is prioritized.
- If **efficacy, toxicity, and costs** are all comparable, then multiple recommendations can be included to accommodate formularies.

How the Committee Selects Primary Treatment Recommendations

If the Committee is not able to follow the process described in this document when selecting a primary treatment recommendation, the proposal to offer multiple comparable recommendations will have to be approved by Via Oncology's Medical Director.



¹ Total estimated costs to payer + patient are calculated by Via staff using the [Via Cost Analyzer](#)


Process for Other Patient Scenarios

The goal of Pathways is to reduce unwarranted variability in care to improve outcomes for patients.

Via Pathway Philosophy & Process

- Even when comparative evidence is not clear, driving to **standardization** based on the consensus of practicing oncologists is better than providing no guidance.
- Pathways are intended to address **common but not all patient presentations**; hence, a goal of 80% On Pathway.
- Other patient scenarios can be created as secondary On Pathway options, but only for specific patient scenarios.
- If the Committee believes that one treatment is more efficacious than another, then that treatment is prioritized.
- If **efficacy, toxicity and costs** are all comparable, then multiple recommendations can be included to accommodate formularies.

How the Committee Selects Alternate Recommendations



¹ When investigating low On Pathway rates or underutilization of On Pathway recommendations, a branch analysis may be informative.

² New FDA approvals or labels are not automatically added as On Pathway recommendations. For a new therapy to be included On Pathway it must supplant a current primary recommendation or contribute towards Via's 80% On Pathway goal by covering a significant proportion of the patient population.

³ Underutilized plans can be removed with approval from Via Oncology's Medical Director.